Lonza Group AG | Balance Sheet

Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
306
218
277
274
491
Total Accounts Receivable
666
683
620
717
905
Inventories
747
898
893
897
1,177
Other Current Assets
95
76
54
177
182
Total Current Assets
1,814
1,875
1,844
2,065
2,755
Net Property, Plant & Equipment
2,494
2,466
2,366
2,412
3,198
Total Investments and Advances
19
24
20
31
36
Long-Term Note Receivable
69
1
1
1
5
Intangible Assets
1,849
2,007
1,951
2,255
7,703
Other Assets
28
21
19
26
82
Total Assets
6,541
6,789
6,588
7,167
14,240
ST Debt & Current Portion LT Debt
236
528
524
289
516
Accounts Payable
286
262
292
284
400
Income Tax Payable
86
77
89
88
196
Other Current Liabilities
551
685
671
971
1,061
Total Current Liabilities
1,159
1,552
1,576
1,632
2,173
Long-Term Debt
2,245
1,693
1,414
1,571
3,730
Provision for Risks & Charges
420
774
806
807
679
Deferred Taxes
293
209
208
291
749
Other Liabilities
30
36
62
134
195
Total Liabilities
4,415
4,659
4,453
4,812
7,987
Common Equity (Total)
2,126
2,130
2,135
2,355
6,205
Total Shareholders' Equity
2,126
2,130
2,135
2,355
6,205
Total Equity
2,126
2,130
2,135
2,355
6,253
Liabilities & Shareholders' Equity
6,541
6,789
6,588
7,167
14,240
Accumulated Minority Interest
-
-
-
-
48

About Lonza Group

View Profile
Address
Muenchensteinerstrasse 38
Basel Basel-Stadt (Basle Town) 4002
Switzerland
Employees -
Website http://www.lonza.com
Updated 09/14/2018
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the Pharma&Biotech and Specialty Ingredients segemnts. The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and testing products and services.